Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06445322 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 7 entries
    • Study sites: 8 to 9
    • Eligibility criteria expanded, about 5 words
  2. Study title expanded, about 1 wordv9
  3. Site details revised at 1 of 8 sitesv8
  4. Study title expanded, about 1 wordv7
  5. Site details revised at 1 of 8 sitesv6
Show 4 earlier versionsHide 4 earlier versions
  1. Site details revised at 1 of 8 sitesv5
  2. Re-verified, no change to tracked fieldsv4
  3. Study sites: 4 to 8v3
  4. Start date changed from estimate of May 30, 2024 to Jun 20, 2024v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.
Trial Details
NCT Number NCT06445322
Lead Sponsor Ascidian Therapeutics, Inc
Conditions
(from sponsor)		 Stargardt Disease, Stargardt Disease 1, Cone Rod Dystrophy, Juvenile Macular Degeneration
Related terms Cone-Rod Dystrophies, Stargardt Disease
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov